T12255	UBERON:0002367 45 53	Prostate
T12256	UBERON:0002367 171 179	prostate
T12257	UBERON:0002530 230 234	lost
T12258	UBERON:0002567 323 333	variations
T12259	UBERON:0002080 447 457	decreasing
T12260	UBERON:0004103 686 699	comparatively
T12261	UBERON:0003675 819 820	.
T12262	UBERON:0002250 853 865	inactivation
T12263	UBERON:0000085 958 965	biology
T12264	UBERON:0007376 1007 1014	targets
T12265	UBERON:0003037 1105 1108	the
T12266	UBERON:0000964 1210 1216	cancer
T12267	UBERON:0001091 1278 1285	homolog
T12268	UBERON:0004851 1383 1393	frequently
T12269	UBERON:0001753 1461 1465	have
T12270	UBERON:0004341 1558 1562	PTEN
T12271	UBERON:0000988 1719 1722	two
T12272	UBERON:0001464 1809 1811	in
T12273	UBERON:0001463 2008 2011	one
T12274	UBERON:0000976 2134 2138	were
T12275	UBERON:0001893 2232 2234	or
T12276	UBERON:0001091 2470 2473	has
T12277	UBERON:0002532 2567 2568	e
T12278	UBERON:0001686 2674 2676	is
T12279	UBERON:0014502 2785 2789	2000
T12280	UBERON:0000979 2926 2931	tumor
T12281	UBERON:2002293 3045 3056	preclinical
T12282	UBERON:0000010 3194 3198	dose
T12283	UBERON:0001091 3326 3329	has
T12284	UBERON:0000119 3435 3439	cell
T12285	UBERON:0002367 10343 10351	prostate
T12286	2 10452 10453	(
T12287	UBERON:0008201 10702 10707	PBMCs
T12288	UBERON:0002531 10890 10894	when
T12289	UBERON:0000948 11051 11058	further
T12290	UBERON:2002283 11335 11337	),
T12291	UBERON:0004340 11582 11585	all
T12292	UBERON:0001488 12257 12259	at
T12293	UBERON:0004605 12376 12378	40
T12294	UBERON:0003675 12645 12646	.
T12295	UBERON:0001488 12749 12751	at
T12296	UBERON:0001754 12849 12855	Figure
T12297	UBERON:0001013 12973 12977	size
T12298	UBERON:0004302 13133 13135	2F
T12299	UBERON:0009912 13142 13147	lobes
T12300	UBERON:0009912 13249 13254	lobes
T12301	UBERON:0001450 13271 13272	,
T12302	UBERON:0002186 13353 13355	by
T12303	UBERON:0001450 13486 13487	,
T12304	UBERON:0000970 13571 13575	foci
T12305	UBERON:0000976 13777 13779	we
T12306	UBERON:0001490 13857 13859	et
T12307	UBERON:2002283 13869 13871	),
T12308	UBERON:0002387 13964 13971	mutants
T12309	UBERON:0001450 14091 14092	,
T12310	UBERON:0002828 14159 14161	of
T12311	UBERON:0001450 14346 14347	,
T12312	UBERON:0002387 14421 14428	mutants
T12313	UBERON:0000305 14679 14680	)
T12314	UBERON:0002828 14738 14740	of
T12315	UBERON:0003037 14842 14845	the
T12316	UBERON:0000979 14902 14906	this
T12317	UBERON:0000180 14971 14978	flanked
T12318	UBERON:0002037 15037 15040	Neo
T12319	UBERON:0001790 15120 15121	-
T12320	UBERON:0001428 15159 15161	).
T12321	UBERON:0000075 15165 15170	these
T12322	UBERON:0003037 15256 15259	the
T12323	UBERON:0002828 15475 15477	of
T12324	2 15567 15568	(
T12325	UBERON:0004546 15606 15614	expected
T12326	UBERON:0000976 15697 15701	were
T12327	UBERON:0000979 15781 15785	this
T12328	UBERON:0002037 15845 15848	Cre
T12329	UBERON:0001828 15990 15991	;
T12330	UBERON:0001428 16006 16008	).
T12331	UBERON:0000428 16041 16061	prostatic epithelium
T12332	UBERON:0009967 16160 16176	transgenic lines
T12333	UBERON:0012100 16296 16308	any possible
T12334	UBERON:2000699 16435 16454	essentially resides
T12335	UBERON:0006743 16509 16514	Wu et
T12336	UBERON:0004151 16549 16553	by a
T12337	UBERON:2000003 16732 16743	high levels
T12338	UBERON:0001894 16865 16875	more focal
T12339	UBERON:0006052 17004 17010	and PB
T12340	UBERON:0004044 17271 17277	in the
T12341	UBERON:0001453 17443 17456	described for
T12342	UBERON:0013640 17628 17638	in Ptenpc1
T12343	UBERON:0004796 17799 17816	prostate revealed
T12344	UBERON:0002507 18020 18035	less pronounced
T12345	UBERON:0003450 18163 18178	inactivation in
T12346	UBERON:0001144 18355 18368	difference in
T12347	UBERON:0002367 18563 18571	prostate
T12348	UBERON:0001137 18699 18703	with
T12349	UBERON:0002496 19020 19029	prostates
T12350	UBERON:0005052 19251 19256	cells
T12351	UBERON:0001768 19341 19347	lumens
T12352	UBERON:0000483 19417 19427	epithelial
T12353	UBERON:0000023 19502 19507	round
T12354	UBERON:0005062 19627 19630	and
T12355	UBERON:0001463 19845 19848	one
T12356	UBERON:0000916 20165 20169	well
T12357	UBERON:0002828 20337 20339	of
T12358	UBERON:0001463 20511 20513	to
T12359	UBERON:0003037 20607 20610	the
T12360	UBERON:0003129 20803 20804	8
T12361	UBERON:0001464 20913 20915	in
T12362	UBERON:0000010 21054 21058	dose
T12363	UBERON:2002270 21142 21153	progressive
T12364	UBERON:0000976 21342 21346	were
T12365	UBERON:0000483 21510 21520	epithelial
T12366	UBERON:0002367 21562 21570	prostate
T12367	UBERON:0001687 21648 21658	noticeable
T12368	UBERON:0000910 21708 21715	culture
T12369	UBERON:0001466 21914 21918	also
T12370	UBERON:4200248 21956 21968	hypomorphism
T12371	UBERON:0001988 22111 22117	affect
T12372	UBERON:0000088 22163 22165	as
T12373	UBERON:0001451 22367 22378	biochemical
T12374	UBERON:0000975 22412 22419	Sawyers
T12375	UBERON:0001464 22629 22631	in
T12376	2 22672 22673	(
T12377	UBERON:0007376 22812 22816	from
T12378	UBERON:0002396 22863 22868	other
T12379	UBERON:0002353 23051 23061	occurrence
T12380	UBERON:0000978 23098 23102	both
T12381	UBERON:0009118 23219 23224	which
T12382	UBERON:0003037 23263 23266	the
T12383	UBERON:0003062 23357 23361	mTOR
T12384	UBERON:0003675 23399 23400	.
T12385	UBERON:3000081 23503 23513	mechanisms
T12386	UBERON:0000025 23545 23549	case
T12387	UBERON:0001954 23647 23654	p27Kip1
T12388	UBERON:0008799 23841 23852	translation
T12389	UBERON:0000428 33548 33567	prostate epithelium
T12390	UBERON:0003002 33684 33696	reduction to
T12391	UBERON:0013411 33811 33825	whereas Ptenhy
T12392	UBERON:0003037 33920 33926	at the
T12393	UBERON:0000119 34029 34037	of cells
T12394	UBERON:0001988 34201 34216	formations were
T12395	UBERON:0000973 34353 34361	at early
T12396	UBERON:0009870 34476 34483	of Pten
T12397	UBERON:0008607 34692 34709	tumor suppression
T12398	UBERON:0004044 34842 34848	in the
T12399	UBERON:0003124 34995 35005	CaP likely
T12400	UBERON:0018144 35248 35257	process (
T12401	UBERON:0008337 35620 35626	in CaP
T12402	UBERON:0001893 35878 35887	have been
T12403	UBERON:0001969 35999 36010	blotting as
T12404	UBERON:0002386 36086 36091	3 and
T12405	UBERON:0008337 36297 36304	mice  A
T12406	UBERON:0000922 38797 38804	embryos
T12407	UBERON:0000178 39023 39028	below
T12408	UBERON:0000305 39353 39354	a
T12409	UBERON:0005062 39723 39726	and
T12410	UBERON:0004619 39908 39910	′-
T12411	UBERON:0001464 40099 40101	in
T12412	UBERON:0004340 40283 40285	al
T12413	UBERON:0001275 40381 40388	briefly
T12414	UBERON:0001490 41178 41180	et
T12415	UBERON:2000283 41303 41304	–
T12416	UBERON:0002364 41395 41399	anti
T12417	UBERON:0001450 41878 41879	,
T12418	UBERON:0001450 42158 42159	,
T12419	UBERON:0009887 42252 42264	Laboratories
T12420	2 42415 42416	(
T12421	UBERON:0009912 51582 51586	lobe
T12422	UBERON:0000088 51845 51847	as
T12423	UBERON:0009889 52037 52040	p27
T12424	2 52388 52389	(
T12425	UBERON:0012356 52990 52995	onset
T12426	UBERON:0000988 53123 53126	two
T12427	UBERON:0005062 53591 53594	and
T12428	UBERON:0018707 53693 53700	Bladder
T12429	UBERON:0002282 53728 53730	SV
T12430	UBERON:0002353 53747 53758	Macroscopic
T12431	UBERON:0003037 53785 53788	the
T12432	UBERON:0001496 53920 53921	H
T12433	UBERON:0003037 53945 53948	the
T12434	UBERON:0000446 54075 54080	These
T12435	UBERON:0005062 54136 54139	and
T12436	UBERON:0001496 54185 54186	H
T12437	UBERON:0000104 54225 54229	mice
T12438	UBERON:0001754 54329 54335	Figure
T12439	UBERON:0006743 54385 54389	Pten
T12440	UBERON:0006743 54449 54455	Ptenhy
T12441	UBERON:0001790 54498 54499	-
T12442	UBERON:0003037 54584 54590	Ptenpc
T12443	UBERON:0003675 54639 54640	.
T12444	2 54641 54642	(
T12445	UBERON:0001954 54686 54693	p27Kip1
T12446	UBERON:0009856 54720 54727	develop
T12447	UBERON:0009005 54738 54751	Possibilities
T12448	UBERON:0002389 54804 54812	findings
T12449	UBERON:0003695 55206 55215	Footnotes
T12450	UBERON:0003037 55240 55243	The
T12451	UBERON:4200005 55287 55295	interest
T12452	UBERON:0003671 55304 55310	Author
T12453	UBERON:0002531 55326 55329	LCT
T12454	UBERON:2005080 55345 55347	AD
T12455	UBERON:0002531 55412 55415	LCT
T12456	UBERON:2005080 55431 55433	AD
T12457	UBERON:0002531 55469 55472	LCT
T12458	UBERON:2005080 55488 55490	AD
T12459	UBERON:0004302 55540 55542	PR
T12460	UBERON:0005062 55556 55559	and
